$BIT:ASX - BIOTRON LIMITED - Promising progress

Their letter to shareholders didn't come out with much fanfare, but I like the space they are operating in. Couple of things that caught my eye was their successful trial in 2018 of their HIV product and they have spent the last year analysing the data out of it and they are soon holding a Scientific/Clinical Advisory Meeting with internationally recognised HIV-1 experts. This might give them a bit of a credibility bump and publicity which often comes out of these kinds of things as they release more PR around the meeting and the feedback.

During the second half of 2019, they are planning to consult with the USA Food and Drug Administration (FDA) to ensure the proposed path is in accordance with relevant regulations.

Also, the positive outcomes from the trial also mean that Biotron has been meeting with key potential partners with compelling Phase 2 data in hand. Phase 2 is generally considered the best time to license technology to a major pharmaceutical company as they have the expertise and resources necessary for late stage clinical development and regulatory approvals in major markets such as the USA

Spiked up around 20% today on top of yesterdays run, so I'd want to see what happens tomorrow. Buyers and seller pretty evenly matched. Might be worth a watch.

Biotron Limited (BIT) is a biotechnology company engaged in research, development, and commercialisation of drugs targeting viral diseases with unmet medical need. The Company focuses on the progression of the clinical development of the drug, BIT225, an investigational, orally-administered, novel antiviral compound in development by Biotron for treatment of HCV and HIV infections.

Comment:

Went the wrong way and lost all of its gain so no trade, but still on my watch list. I do think they could be a winner over the next few weeks / months.